NCT03460327 Bariatric Surgery and Pharmacokinetics of Candesartan
| NCT ID | NCT03460327 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Norwegian University of Science and Technology |
| Condition | Obesity, Morbid |
| Study Type | OBSERVATIONAL |
| Enrollment | 12 participants |
| Start Date | 2016-11-02 |
| Primary Completion | 2026-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 12 participants in total. It began in 2016-11-02 with a primary completion date of 2026-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Changes to gastric pH, gastric emptying time, gastrointestinal transit-time or the pre-systemic metabolizing effect of enzymes secreted in the mucosa may all alter the pharmacokinetics of medicines. These factors are potentially influenced by bariatric surgery. Little is so far known about how gastric bypass and sleeve gastrectomy impacts the biological availability of medication. In this study the pharmacokinetic effects of bariatric surgery on candesartan are investigated.
Eligibility Criteria
Inclusion Criteria: * Preparing to undergo gastric bypass or sleeve gastrectomy in Central Norway * Being a Norwegian citizen Exclusion Criteria: * Having previously undergone resections in the GI-tract
Contact & Investigator
Magnus Strømmen, MSc
PRINCIPAL INVESTIGATOR
St. Olavs Hospital
Frequently Asked Questions
Who can join the NCT03460327 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Obesity, Morbid. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03460327 currently recruiting?
Yes, NCT03460327 is actively recruiting participants. Contact the research team at magnus.strommen@stolav.no for enrollment information.
Where is the NCT03460327 trial being conducted?
This trial is being conducted at Trondheim, Norway.
Who is sponsoring the NCT03460327 clinical trial?
NCT03460327 is sponsored by Norwegian University of Science and Technology. The principal investigator is Magnus Strømmen, MSc at St. Olavs Hospital. The trial plans to enroll 12 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.